Zura Bio Limited · NASDAQ:ZURA
Zura Bio — Investor Presentation (July 2023)
31 slides from Zura Bio's investor presentation, Jul 27, 2023
Slide 1: Building the Next Immunology Leader
Building the Next Immunology Leader Corporate Presentation – July 2023
Slide 2: Forward-looking statements
©2023 Zura Bio Ltd. This communication includes “ forward - looking statements ” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . Words such as “ expect ,” “ estimate ,” “ project ,” “ budget ,” “forecast,” “ anticipate,” “ intend,” “ plan,
Slide 3: Company highlights
©2023 Zura Bio Ltd. 3 ▪ Experienced management team with proven ability to successfully execute and build a leading market position ▪ Multiple Phase 2 ready assets in important, underserved indications including SSc, HS and Asthma ▪ Public on Nasdaq in March 2023 ▪ Well capitalized with > $100M cash
Slide 4: Experienced management team and board of directors
©2023 Zura Bio Ltd. Experienced management team with proven ability to successfully execute and build a leading market position Verender Badial Chief Financial Officer Someit Sidhu M.D. Chief Executive Officer and Director Chris Cabell M.D. Chief Medical Officer and Head of Research and Development
Slide 5: Sizeable Total Addressable Market Across Validated Mechanisms
©2023 Zura Bio Ltd. Sizeable Total Addressable Market Exists Across Number of Validated Mechanisms 5 Sources: Evaluate Pharma. FactSet. Data as of 07/21/23. (1) Assets included in projected TAM: Cosentyx, Taltz, Bimzelx and Siliq (IL - 17), Tezspire (TSLP), Benlysta (BAFF) and itepekimab and tzoraki
Slide 6: Clinical stage pipeline targeting key immunology pathways
©2023 Zura Bio Ltd. Clinical stage pipeline targeting key immunology pathways Zura Bio Program Indication Next Clinical Phase Expected Key Milestone Preclinical Phase 1 Phase 2 Phase 3 ZB - 106 tibulizumab Anti - BAFFxIL - 17 Systemic sclerosis Hidradenitis suppurative Initiation of asset transfer O
Slide 7: ZB-106 Potential First-in-Class Dual Antagonist
©2023 Zura Bio Ltd. ZB - 106 is a Potential First - in - Class, Dual Antagonist Combining tabalumab and ixekizumab (TALTZ®) 7 ZURA’S LEAD ASSET Source: 1. Liu et al. 2016. J Inflam Research ; 2. Manetta et al. 2014. J Inflam Research ; 3. Benschop et al. 2019. MAbs IgG - scFv engineered by the fusio
Slide 8: ZB-106 Disrupts IL-17 and/or BAFF-Mediated Inflammation
©2023 Zura Bio Ltd. ZB - 106 Disrupts IL - 17 and/or BAFF - Mediated Inflammation 8 ZB - 106 has the potential to treat diseases driven by B - cell and T - cell signaling POTENTIAL T - CELL AND B - CELL SYNERGY ▪ Multiple T - cell driven diseases remain sub - optimally treated despite the growth in
Slide 9: ZB-106 tibulizumab: Systemic sclerosis (SSc)
ZB - 106 tibulizumab | Anti BAFFxIL - 17 | Systemic sclerosis (SSc) Potential First - in - Class, Dual Antagonist Combining tabalumab and TALTZ®
Slide 10: Systemic sclerosis is rare and life-threatening with insufficient therapy
©2023 Zura Bio Ltd. Systemic sclerosis is a rare & life - threatening disease with insufficient therapy available Rare and life - threatening autoimmune disease characterized by tissue inflammation and fibrosis ▪ One of the deadliest of the rheumatic diseases ▪ Associated with severe disability, fib
Slide 11: ZB-106 Clinically De-Risked Through P1b Participants Dosed
©2023 Zura Bio Ltd. ZB - 106 is Clinically De - Risked Through P1b 11 78 Participants Dosed Across Three P1/1b studies 57 participants with single dose; 21 participants with multiple dose up to 12 weeks ▪ SAD Studies: No deaths or SAEs ▪ MAD study: No deaths, single related SAE of neutropenia with r
Slide 12: IL-17 and BAFF Inhibition Have Shown Efficacy in SSc
©2023 Zura Bio Ltd. IL - 17 and BAFF Inhibition Pathways Have Shown Efficacy in Placebo Controlled Trials in Systemic sclerosis (SSc) 12 ZB - 106 has the potential to treat the TH17 and BAFF components of SSc IL - 17 efficacy in SSc ▪ Brodalumab treatment in SSc leads to improved clinical outcomes 1
Slide 13: Treatments in SSc Have Demonstrated Improved Clinical Outcomes
©2023 Zura Bio Ltd. Treatments in SSc have Demonstrated Improved Clinical Outcomes 13 Source: Ebata et al. 2021. Lancet Rheumatol , Gordon et al..2018. ArthRheumatol , Fukasawa et al. 2022. AnnalsRheumDisease ; Gordon et al..2018. ArthRheumatol . CD20+ B cells in HS Lesions Brodalumab IL - 17 recept
Slide 14: Proposed Phase 2 SSc Trial Design
©2023 Zura Bio Ltd. Proposed Phase 2 SSc Trial Design* 14 ▪ mRSS 10 - 29 ▪ Participant presented the first symptoms of sclerosis other than Raynaud's phenomenon within 60 months before enrollment KEY INCLUSION CRITERIA: DOUBLE BLIND, PLACEBO - CONTROLLED TRIAL ~40 participants per arm ZB - 106 DOSE
Slide 15: ZB-106 tibulizumab: Hidradenitis suppurativa (HS)
ZB - 106 tibulizumab | Anti BAFFxIL - 17 | Hidradenitis suppurativa (HS) Potential First - in - Class, Dual Antagonist Combining tabalumab and TALTZ®
Slide 16: Overview of Hidradenitis suppurativa (HS)
©2023 Zura Bio Ltd. Overview of Hidradenitis suppurativa (HS) 16 ▪ Hidradenitis Suppurativa is an inflammatory follicular skin disease ▪ Skin lesions develop in axillae, in the groin, and under the breasts, are formed as a result of inflammation & infection of sweat glands and are characterized by:
Slide 17: Multiple P3 Studies Show IL-17 Is Clinically Validated Pathway in HS
©2023 Zura Bio Ltd. 17 Multiple P3 Studies Shows IL - 17 is Clinically Validated Pathway to Treat HS Phase 2 data show efficacy ceiling may have been reached Fostamatinib data provide evidence of B - Cell importance Sources: Company Presentations, Publications and Research. 1. Represents data from p
Slide 18: Addition of BAFF Has Potential to Provide Superior Efficacy to IL-17 Alone
©2023 Zura Bio Ltd. Addition of BAFF has Potential to Provide Superior Efficacy to IL - 17 Alone 18 Clinical data in HS ▪ B cell depletion with rituximab provided therapeutic benefit 5 ▪ 4/5 cases report complete remission of HS lesions 5 ▪ Modulating B cell function using fostamatinib (SYK inhibiti
Slide 19: Dermal Tunnels: Role in HS Pathogenesis
©2023 Zura Bio Ltd. Dermal Tunnels: Role in HS Pathogenesis ▪ Recent literature highlights the role of dermal tunnels in the pathogenesis of HS 1,2 ▪ The presence of dermal tunnels increased the amount of time needed to achieve HiSCR50 with adalimumab 3 ▪ One significant drawback of the HiSCR is the
Slide 20: Proposed Phase 2 HS Trial Design
©2023 Zura Bio Ltd. Proposed Phase 2 HS Trial Design* 20 ▪ Moderate to Severe HS ▪ Hurley Stage II/III ▪ Total abscess and inflammatory count (AN) ≥ 3 KEY INCLUSION CRITERIA: DOUBLE BLIND, PLACEBO - CONTROLLED TRIAL ~40 participants per arm ZB - 106 DOSE LEVEL 1 ZB - 106 DOSE LEVEL 2 PRIMARY EFFICAC
Slide 21: ZB-168 Anti-IL-7R: Alopecia areata (AA)
ZB - 168 Anti - IL - 7R | Alopecia areata (AA) A Potential Best - in - Class Anti - IL - 7R Inhibiting Both IL - 7 and TSLP Pathways
Slide 22: ZB-168 Asset Overview
©2023 Zura Bio Ltd. 22 ZB - 168 – Asset Overview Source: 1. doi : 10.1038/s41467 - 018 - 06804 - y, 2. 10.1172/jci.insight.126054, 3. Clinical study report, 4. doi:10.3389/fimmu.2020.01557, 5. https ://www.frontiersin.org/articles/10.3389/fimmu.2020.01557/full, 6. Herold, K. C. et a. JCI Insight. 20
Slide 23: TSLP and IL-7 Have a Broad Impact on Epithelial-Driven Inflammation
©2023 Zura Bio Ltd. 23 TSLP and IL - 7 have a Broad Impact on Epithelial - Driven Inflammation TSLP AND IL - 7 PATHWAYS • Thymic stromal lymphopoietin (TSLP) is an epithelial - derived cytokine primarily expressed in the lungs, skin and gastrointestinal tract 1 • TSLP is released from the epithelium
Slide 24: ZB-168 Is Potentially Best-in-Class Asset at TSLP Inhibition
©2023 Zura Bio Ltd. ZB - 168 is Potentially Best - in - Class Asset at TSLP Inhibition 24 ZB - 168 (IL - 7R α ) UPB - 101 ( α - TSLPR) Tezepelumab (TSLP) ADX - 914 (IL - 7R α ) IL - 7R α mAb α - TSLPR mAb TSLP mAb IL - 7R α mAb TSLP - Induced Signals ▪ 7.5 ng/ml / 0.05nM (CCL17) (1) ▪ 11 ng/ml / 0.0
Slide 25: ZB-168 Is Impactful on T Effector Memory Cells
©2023 Zura Bio Ltd. ZB - 168 is Impactful on T effector Memory Cells 25 Source: 1. doi : 10.1172/jci.insight.126054, 2. doi:10.1208/s12248 - 019 - 0401 - 3 CLINICAL DATA IN PARTICIPANTS DEMONSTRATES IMPACT ON KEY T - CELL SUBPOPULATIONS CD8+ T effector cells 1 Dose 1 Dose 2 Dose 3 Dose 4 ▪ Dose depe
Slide 26: ZB-880 torudokimab Anti-IL-33: Asthma
ZB - 880 torudokimab | Anti - IL - 33 | Asthma A Potential Best - in - Class Anti - IL - 7R Inhibiting Both IL - 7 and TSLP Pathways
Slide 27: ZB-880 Asset Overview
©2023 Zura Bio Ltd. 27 ZB - 880 Asset Overview About ZB - 880 (torudokimab) ▪ IL - 33 implicated in driving Th2 biology through ST2 and Th1/Th17 through alternative signaling 1 ▪ Well tolerated in Ph1 and Ph2 trials conducted by Eli Lilly 2 - 141 healthy volunteers in Ph1 study - 103 participants wi
Slide 28: ZB-880 IL-33 Pathway
©2023 Zura Bio Ltd. 28 ZB - 880 IL - 33 Pathway IL - 33 PATHWAY ▪ IL - 33 is a member of the IL1 cytokine family that is constitutively expressed in structural and lining cells including fibroblasts, endothelial, and epithelial cells of skin, gastrointestinal tract, and lungs 1 ▪ IL - 33 is released
Slide 29: ZB-880 Has Potential for Best-in-Class Activity
©2023 Zura Bio Ltd. ZB - 880 Has Potential for “Best - in - Class” Activity 29 Antibody k on (M - 1 s - 1 ) k off (s - 1 ) k d ( pM ) Torudokimab Potency torudokimab (LY3375880) 1.7 x 10 6 6.7 x 10 - 5 39 etokimab ( AnaptysBio ) 9.4 x 10 5 1.2 x 10 - 4 112 2.9x itepekimab (Regeneron) 7.6 x 10 5 1.6
Slide 30: Financial Summary and Milestones
©2023 Zura Bio Ltd. 30 Financial Summary and Milestones CASH, CASH EQUIVALENTS & INVESTMENTS $118.2 million 1 MARKET CAP $398 million 2 TOTAL SHARES OUTSTANDING Fully Diluted, incl warrants, options 1 66,765,163 1 COVERING ANALYSTS Yatin Suneja , Guggenheim Securities Steven Seedhouse, PhD , Raymond
Slide 31: zurabio.com
zurabio.com